Lansoprazol Ratiopharm

Lansoprazole, the active ingredient in Lansoprazol Ratiopharm, is a proton pump inhibitor presented as an oral dosage form for gastroenteral use. It reduces gastric acid secretion and is prescribed for conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease and Helicobacter pylori eradication regimens.

GNH USA supplies Lansoprazol Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazol Ratiopharm is a proton pump inhibitor that lowers gastric acidity in several acid‑related disorders. - Gastro‑oesophageal reflux disease: reduces acid exposure and promotes healing of the esophageal lining. - Peptic ulcer disease: facilitates ulcer healing by suppressing gastric acid production. - Erosive esophagitis: alleviates mucosal damage caused by chronic acid reflux. - Helicobacter pylori eradication regimen: enhances the effectiveness of antibiotic therapy by creating a less acidic gastric environment.

Lansoprazol Ratiopharm may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Diarrhoea: loose stools that may resolve with continued use. - Nausea: feeling of unease or upset stomach. - Abdominal pain: discomfort or cramping in the stomach area.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rapid onset of rash, swelling, and breathing difficulty. - Low magnesium levels (hypomagnesemia): may cause muscle cramps, irregular heartbeat. - Clostridioides difficile infection: severe diarrhoea due to bacterial overgrowth.

Before initiating therapy, consider the following precautions. - Renal function assessment: adjust use in patients with severe renal impairment. - Magnesium monitoring: periodic checks recommended during long‑term therapy. - Hepatic impairment: use with caution in patients with liver disease. - Discontinuation: avoid abrupt stopping to prevent rebound acid hypersecretion. - Store at ambient temperature: keep in the original pack, protect from moisture.

Lansoprazol Ratiopharm can affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Clarithromycin: potent CYP2C19 inhibition may increase lansoprazole levels. - Ketoconazole: reduced absorption of ketoconazole due to increased gastric pH. - Atazanavir: decreased atazanavir exposure, compromising antiviral efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: possible enhancement of anticoagulant effect, monitor INR. - Digoxin: modest increase in serum digoxin concentrations. - Methotrexate: reduced clearance may raise toxicity risk.